Kyverna Therapeutics Target Price

Where could KYTX trade next? Consensus target price: $25.

Get informed when a big investor buys or sells

+ Follow

Share Price

$6.81

Average Target Price

$25.00

267.1% upside

1 analysts in the last 4 months

High: $25 | Low: $25

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-09-25	Needham	$25	267.1% upside
2026-05-15	H.C. WainwrightMitchell Kapoor	$25	267.1% upside
2025-12-16	Wells Fargo	$33	384.6% upside
2025-12-15	UBS	$32	369.9% upside
2025-12-15	Morgan StanleyMichael Ulz	$33	384.6% upside
2025-12-04	Morgan StanleyMichael Ulz	$25	267.1% upside
2025-10-27	H.C. Wainwright	$20	193.7% upside
2025-08-29	H.C. Wainwright	$10	46.8% upside

Kyverna Therapeutics (KYTX) FAQ

The latest target price for KYTX is $25. Investors often review this figure alongside Kyverna Therapeutics's historical trend and sector peers before judging valuation or financial health.

Kyverna Therapeutics trades near $6.81 while the consensus target sits at $25 (267.1% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting KYTX's target price ($25), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.